You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

CLINICAL TRIALS PROFILE FOR HOMOHARRINGTONINE

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Homoharringtonine

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00002574 ↗	Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.
NCT00003239 ↗	Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
NCT00003239 ↗	Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
NCT00003694 ↗	Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase	Completed	National Cancer Institute (NCI)	Phase 2	Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
NCT00004933 ↗	Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa	Terminated	National Cancer Institute (NCI)	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if homoharringtonine is more effective than hydroxyurea for chronic myelogenous leukemia that has not responded to interferon alfa. PURPOSE: Randomized phase III trial to compare the effectiveness of homoharringtonine with that of hydroxyurea in treating patients who have chronic myelogenous leukemia that has not responded to interferon alfa.
NCT00004933 ↗	Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa	Terminated	Alliance for Clinical Trials in Oncology	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if homoharringtonine is more effective than hydroxyurea for chronic myelogenous leukemia that has not responded to interferon alfa. PURPOSE: Randomized phase III trial to compare the effectiveness of homoharringtonine with that of hydroxyurea in treating patients who have chronic myelogenous leukemia that has not responded to interferon alfa.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Homoharringtonine

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Acute Myeloid Leukemia	6
Leukemia	6
Secondary Acute Myeloid Leukemia	3
Chronic Phase Chronic Myelogenous Leukemia	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Leukemia, Myeloid	26
Leukemia	26
Leukemia, Myeloid, Acute	17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Homoharringtonine

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	68
China	38
France	3
Poland	2
Germany	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Texas	12
Massachusetts	4
New York	4
California	3
Maryland	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Homoharringtonine

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	7
Phase 2/Phase 3	2
Phase 2	16
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	15
Completed	9
Terminated	4
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Homoharringtonine

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
National Cancer Institute (NCI)	7
ChemGenex Pharmaceuticals	4
The First Affiliated Hospital of Soochow University	4
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Other	49
Industry	20
NIH	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.